Immunogenicity of a New Enhanced Tetanus-reduced Dose Diphtheria-acellular Pertussis (Tdap) Vaccine Against Bordetella Pertussis in a Murine Model

Kyu Ri Kang
Catholic University of Korea

Dong Ho Huh
The Vaccine Bio Research Institute, Catholic University of Korea

Ji Ahn Kim
The Vaccine Bio Research Institute, The Catholic University of Korea

Jin Han Kang (kjhan@catholic.ac.kr)
Catholic University of Korea School of Medicine

Research article

Keywords: Tetanus-reduced dose diphtheria-acellular pertussis vaccine, immunogenicity, mouse study

DOI: https://doi.org/10.21203/rs.3.rs-127484/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the former vaccine GC3111 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, the immunogenicity and efficacy of the enhanced Tdap vaccine were compared and evaluated between the former Tdap vaccine GC3111 and the commercially available Tdap vaccine in a murine model.

Methods

Balb/C mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 6 weeks using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The INF-γ (Th1), IL-5 (Th2), and IL-17 (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens. An intranasal challenge test was performed 4 weeks after booster vaccination.

Results

The enhanced GC3111 generated a humoral response to filamentous hemagglutinin (FHA) that was comparable to that of the commercial vaccine. Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between the groups. All the vaccinated groups indicated a Th1/Th2 response. The mean value of INF-γ in the control and study groups (simulated with hBp mixed with antigens) was 12,551.69, and the mean value of IL-5 (simulated with antigens) was 1,782.47 pg/mL. On Day 5 post-intranasal challenge, B. pertussis colonies were absent in the lungs in all groups.

Conclusions

Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.

Background

Sporadic outbreaks of pertussis among adolescents and adults have continuously been reported worldwide, including in advanced countries such as Europe, Australia, the USA, and Japan, where the rate
of vaccination is above 90%, and yet, the disease is spreading steadily [1–3]. The reasons for the increased occurrence of pertussis include the following. The antibodies produced after pertussis vaccination last for approximately 5–6 years, and thus, the likelihood of reinfection increases during adolescence and adulthood, wherein the defence mechanism is lost due to the waning of the antibodies produced by the diphtheria-tetanus-pertussis (DTP) vaccine. Moreover, the present pertussis vaccine does not work against variant pathogenic strains, such as pertactin (PRN)-deficient variants [4–6], particularly in advanced countries, where the acellular pertussis vaccine (aP vaccine) is widely used. In addition, the pertussis vaccination rate is reported to be low in adolescents and adults. Furthermore, tolerance to macrolide antibiotics following pertussis outbreaks is a major challenge in some countries [7]. Therefore, to address the epidemiological changes, Tdap vaccination should be recommended to adolescents and adults, and simultaneously, new vaccines that protect against variant strains should be developed.

In Korea, the Korea National Institution of Health established the laboratory diagnostics of pertussis in 1999, and since then, only 18 incidences were observed annually until 2008. However, the numbers increased subsequently, with 66 cases in 2009, 27 in 2010, and 97 cases observed in 2011 [8]. In the first half of 2012, sudden small outbreaks were reported around the schools in certain regions. Since then, small sporadic outbreaks have continued to occur with a steady increasing trend. With epidemiological changes in Korea, immunization of adolescents and adults using the adult pertussis vaccine is necessary [9, 10]. Currently, no Tdap vaccine manufacturer exists in Korea, so the country relies on imported vaccines. Therefore, vaccination is limited, as the vaccine is not easily available. To resolve this issue, Green Cross Pharma (GC Pharma, Yongin, Korea) began developing a Tdap vaccine (GC3111) in 2010 and began Phase I and IIa clinical trials in 2017. During the trials, the antibody titre against pertussis toxin (PT), filamentous hemagglutinin antigen (FHA), and PRN antigens revealed positive seroconversion and seroprotection after vaccination; however, the vaccine induced a lower titre level of the antibody to FHA compared to the commercially available control vaccine Boostrix™ (GlaxoSmithKlein, Rixensart, Belgium). Based on this finding, an enhanced GC3111 Tdap vaccine with increased antigen volume was developed by improving FHA inactivation and purification. The present study aimed to investigate whether the enhanced vaccine (enhanced GC3111) had improved immunological outcomes and efficacy by comparing the former vaccine (GC3111) and the existing commercial vaccine using an animal-based model prior to conducting human trials.

**Methods**

**Mice**

During the animal research period, the mouse were housed in filter-top cages under semi-specific pathogenfree conditions and food and water are available freely. All animal research procedures were performed in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals and the Guidelines and Policies for Rodent Experiments provided by the IACUC (Institutional Animal Care and Use Committee) in the School of Medicine, The Catholic University of Korea. (Approval number: CUMS-2019-0100-01).
**Immunization**

Four-week-old BALB/c female mice from Orient-bio Co., Ltd. (Seongnam, Korea) were used. The mice were divided into 4 groups (30 mice per group) according to booster vaccine types: negative control boosted with saline, positive control with licensed Tdap vaccine (Boostrix™) from GSK (GlaxoSmithKline, Rixensart, Belgium) and two study groups; one study group with the previous GC Pharma Tdap vaccine GC3111 and the other study group with the enhanced FHA antigen of GC 3111 vaccine. All mice were vaccinated with one-fourth of the human dose (0.125 mL) via intramuscular (quadriceps muscle) injection and immunized with two doses of primary diphtheria-tetanus-acellular pertussis (DTaP) vaccine (provided by GC Pharma) at 3-week intervals, except for the negative control group, which was vaccinated with saline before booster vaccination. The study was conducted according to previous murine model studies at our laboratory at the Vaccine Bio Research Institute [11-12]. All Tdap vaccine components were equivalent to PT 8 μg, FHA 8 μg, and PRN 2.5 μg. The vaccination and assay schedule is described in Fig. 1.

**Humoral immunity assessment**

Blood samples from the retro-bulbar venous plexuses were collected in each group at 1 week before booster vaccination (n=6 per group) and 2, 4 week after booster vaccination (n=10). When sampling the blood, all mice were anesthetized with tiletamine, zolazepam and xylazine via intra peritoneal injection except last sampling. At 4 week after booster vaccination, mice were euthanized by 2% isoflurane inhalation while sampling and sacrificed via CO₂ inhalation. The humoral immunogenicity against pertussis antigens (anti-PT IgG, anti-FHA IgG and anti-PRN IgG) was evaluated by commercially available ELISA kits (Alpha Diagnostic International Inc., San Antonio, TX, USA). Additionally, anti-diphtheria toxoid (DT) IgG and antitetanus toxoid (TT) IgG titres were measured using commercially available ELISA kits (Alpha Diagnostic International Inc. San Antonio, TX, USA). All final results were analysed through optimal density using an Epoch ELISA plate reader (BioTek Instrument Inc., Winooski, VT, USA). Antibody titres of each tested antigen were compared between groups at each time point.

**Cellular mediated immunity assessment**

Four weeks after the booster vaccination, mouse spleen cells (n=5 per group) were prepared in RPMI-1640 (HyClone, GE Healthcare Life Sciences, SouthLogan, Utah, USA) medium containing penicillin, streptomycin, and 10% FBS. For cell-based experiments, 1 μg/mL pokeweed mitogen (PWM; Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control, and the following three stimulators were tested: 1 × 10⁶ CFU/mL of heat inactivated Bordetella pertussis (hBp), PT (8 μg/mL), FHA (8 μg/mL) and PRN (4 μg/mL) vaccine antigens, and the mixture of the two (hBp + antigens). Splenocytes (5 × 10⁶ cells/mL) were treated with three simulators separately and cultured in 6-well plates for 3 days. Subsequently, the cytokine response was assessed by analysing the supernatant using ELISA kits (R&D Systems, Minneapolis, MN, USA).

**Intranasal challenge test**
The protective efficacy against *B. pertussis* infection was assessed with intranasal clearance tests. The challenge *B. pertussis* strain obtained from a Korean adult pertussis patient was supplied from the Korean Centers for Disease Control & Prevention (No. 13674) and was intranasally inoculated at $6 \times 10^6$ colony forming units (CFUs) 4 weeks after booster vaccination. Four mice in each group were euthanized by 2% isoflurane inhalation and their lungs were extracted 2 h, 2 days, 5 days and 8 days after infection. The extracted lungs were homogenized in 10 mL of PBS and diluted to concentrations of $10^{-1}$, $10^{-3}$ and $10^{-5}$. Each diluted homogenate was incubated on Bordet-Gengou agar media at 37 °C for 5 days. CFUs on each media were determined, and mean CFUs were compared between groups at each time point.

**Statistical analysis**

All results are expressed as the means ± standard errors of the means (SEM) and compared by two-way ANOVA with Tukey's multiple comparison test. Statistical analysis was performed using GraphPad Prism™ software v7.02 (GraphPad, San Diego, CA, USA), and statistical significance was defined as a p value (*p* < 0.05, **p** < 0.01, ***p** < 0.001, ****p** < 0.0001).

**Results**

**Humoral response**

The humoral immune response was examined 1 week before (n = 6 per group) and 2 and 4 weeks (n = 10 per group) after the booster vaccination. In the anti-DT IgG and anti-TT IgG humoral response, the enhanced GC3111 group led to a high titre among the groups (Fig. 2A). Humoral immunity against pertussis antigens was significantly elevated in the positive control group and the two study groups compared with the negative control group. The enhanced GC3111 group was not significantly different from the other groups; however, a statistically significant difference was noted in anti-FHA IgG titre between the GC3111 group and the positive control group. The mean anti-FHA IgG titre 2 weeks after booster vaccination was 73.10 U/mL in the GC3111 group and 117.70 U/mL in the positive control group ($p = 0.0109$, ***p** < 0.05). Four weeks after booster vaccination, the anti-PRN IgG titre was higher in the GC3111 group than in the positive control group ($p = 0.0427$, ***p** < 0.05; Table 1, Fig. 2B).
|                             | Negative control | Positive control | GC3111       | Enhanced GC3111 |
|-----------------------------|------------------|------------------|--------------|-----------------|
| **Anti-PT IgG (U/mL)**      |                  |                  |              |                 |
| Naïve (N = 5)               | 0.86 ± 0.17      | 0.55 ± 0.16      | 0.66 ± 0.16  | 0.82 ± 0.31     |
| 1w before booster vaccination (N = 6) | 0             | 9,804.25 ± 1,061.82 | 8,102.17 ± 1,002.83 | 10,608.92 ± 2,022.17 |
| 2w after booster vaccination (N = 10) | 92.20 ± 63.98 | 15,457.80 ± 1,781.44 | 11,734.00 ± 886.59 | 16,580.25 ± 1,663.38 |
| 4w after booster vaccination (N = 10) | 0             | 22,270.00 ± 3,286.30 | 19,936.00 ± 2,972.66 | 19,203.90 ± 3,494.35 |
| **Anti-FHA IgG (U/mL)**     |                  |                  |              |                 |
| Naïve (N = 5)               | 0.01             | 0.01             | 0.01         | 0.02 ± 0.01     |
| 1w before booster vaccination (N = 6) | 0.88 ± 0.22 | 51.41 ± 9.98     | 48.39 ± 11.00 | 40.74 ± 7.85    |
| 2w after booster vaccination (N = 10) | 0              | 117.70 ± 17.95  | 73.10 ± 15.04 | 93.90 ± 16.80   |
| 4w after booster vaccination (N = 10) | 7.50 ± 3.84 | 78.00 ± 8.79     | 60.50 ± 3.45  | 62.00 ± 6.35    |
| **Anti-PRN IgG (U/mL)**     |                  |                  |              |                 |
| Naïve (N = 5)               | 0                | 0                | 0            | 0               |
| 1w before booster vaccination (N = 6) | 2.88 ± 2.80 | 510.42 ± 42.25   | 436.08 ± 38.92 | 456.75 ± 52.19  |
| 2w after booster vaccination (N = 10) | 96.40 ± 96.40 | 2,181.00 ± 225.35 | 2,629.10 ± 272.59 | 2,686.10 ± 320.84 |
| 4w after booster vaccination (N = 10) | 18.90 ± 18.90 | 1,491.50 ± 127.52 | 2,101.40 ± 73.77 | 1,918.10 ± 237.37 |

(SEM = standard errors of the means)

**Cell mediated immune response**

Cell-mediated immunity (CMI) was evaluated by stimulating mouse splenocytes (n=5 per group) to hBp, vaccine antigens, or hBp+ antigens, whereas the culture medium was used as a negative control, and 1 μg/mL PWM was used as a positive control. The results showed that the secretion of INF-γ, IL-17A, and
IL-5 did not differ significantly among the groups (except for the media negative control group and PWM control group). However, cytokine secretion was significantly different according to the stimulator used; the mean INF-γ expression levels of the three vaccinated groups, including the positive control and 2 study groups, were 12,551.69 pg/mL in the hBp+antigen stimulator and 2,289.63 pg/mL in the pertussis antigen stimulator. Even after excluding the saline-vaccinated negative control group results, the mean value of the vaccinated groups stimulated by hBp+antigen was three times higher than that of the antigen-stimulated group. Furthermore, IL-17A and IL-5 were significantly upregulated in the groups stimulated by the hBp and vaccine antigens, respectively (Fig. 3A). In this study, the CMI of the vaccinated groups confirmed Th1/Th2 immunity when the ratio was computed between the mean cytokine level of the vaccinated groups subtracted from the cytokine level of the negative control (saline vaccinated) group using the highest cytokine response regardless of the stimulators. IL-17A was overexpressed by the hBp stimulator in both the vaccinated groups and the negative control group. The mean titre of the three vaccinated groups was 1,062.67 pg/mL, and that of the negative control group was 1,095.92 pg/mL. When excluding the level of the negative control group from the vaccinated groups, limited IL-17A expression was observed. In contrast, when the level of the negative group was excluded, the mean cytokine response of the three vaccinated groups was 6,826.51 pg/mL and 1773.26 pg/mL for INF-γ and IL-5, respectively (Fig. 3B).

**Intranasal lung clearance**

The vaccine efficacy was evaluated against the clinical pertussis strain (n=4 per group). The results from the test using the clinically isolated strain showed that *B. pertussis* was removed quickly in the lungs and was almost eliminated after 5 days (Fig. 4). The results were the same in the two study groups and the positive control group. The CFUs of *B. pertussis* significantly decreased 2 days after intranasal challenge with the clinical strain in the study and positive control groups (Fig. 4). This result showed protective efficacy against *B. pertussis* in both the positive group and the two study groups.

**Discussion**

Since 2000, a serological study in Korea has confirmed incidents of pertussis infection with higher certainty than reported earlier, and small-scale pertussis outbreaks have occurred once every 3 years since 2009, leading to the requirement for Tdap vaccination. In 2010, GC Pharma, a national company, started developing Tdap and DTaP vaccines; and our laboratory, the Vaccine Bio Research Institute, conducted animal-based studies [11, 12] and performed clinical trials [13] using the Tdap booster vaccine. In animal studies, GC Pharma’s new Tdap vaccine, GC3111, was compared with Boostrix™, a commercially available product in Korea. The humoral immunity was assessed after a single dose of DTaP vaccine followed by Tdap booster vaccine [12], and CMI was assessed after two doses of DTaP vaccine followed by Tdap booster vaccine [11]. After two animal studies and clinical trials, GC Pharma complemented GC3111 to improve the anti-FHA antibody response. The present study aimed to show the immunogenic response and efficacy of complemented GC3111 (enhanced GC3111) compared to Boostrix™ and the former GC3111 vaccine and to verify anti-FHA response reinforcement.
The protective effects of the humoral response to the aP vaccine were actively investigated soon after aP vaccine development, and the importance of the humoral response to PT, PRN, FHA, and fimbriae antigens was evaluated in different systems, including animal models [14–16]. Humoral immunity to these antigens of *B. pertussis* is known to protect the individual from pertussis infection by neutralizing the pathogenic antigens or by activating the complement system that activates CMI [14, 17, 18]. Among the immunogens present in the vaccine, PT is known as the most important immunogen and induces the generation of protective antibodies that provide direct protection from pertussis infection [19, 20]. Moreover, the humoral immunity generated by aP-vaccinated pregnant women can prevent infants from pertussis infection since the antibodies produced by the mother can deliver to the foetus [21–24]. Thus, evaluation of humoral response after pertussis vaccination is immensely significant. In this study, compared to the positive control, the GC3111 group showed a significantly lower anti-FHA antibody level 2 weeks after booster vaccination, which was in line with the observations of a previous study [13]; however, the antibody response was comparable between the enhanced GC3111 group and the positive control group with respect to all antigens and all time points (Fig. 2B). Hence, our results verified that the humoral immune response was improved with the enhanced GC3111 Tdap vaccine. With respect to the effect of two doses of DTaP vaccination, anti-PT, anti-FHA, and anti-PRN antibody titres were elevated even before the booster vaccination, and these levels were further enhanced after the booster vaccination and retained at a high level until 4 weeks after vaccination (Fig. 2B). Considering the humoral responses to tetanus and diphtheria, all groups except the negative control group revealed a titre of over 0.1 U/mL (the protective level) from 1 week before booster vaccination, and this is predicted by two doses of DTaP vaccination (Fig. 2A).

The fact that CMI plays crucial roles in preventing pertussis infection was first shown in a mouse model in 1993 [25] followed by clinical experiments [26]. The importance of both Th1 [27, 28] and Th17 [29–31] type CMI responses was confirmed in animal and clinical studies. INF-γ and IL-17 are the main cytokines that provide crucial protection. Recently, the resurgence of pertussis outbreaks [1–3] and the protective effects of the aP vaccine and whole cell pertussis (wP) vaccine [32] were compared frequently. This was based on the observations of some researchers who concentrated that the wP vaccine induces Th1/Th17 responses similar to natural infection [31, 33, 34], whereas the aP vaccine mainly induces the Th2 response, resulting in a weaker protective effect than that of the wP vaccine. Previous studies showed that the aP vaccine generated Th1/Th2 [35] or Th2/Th17 [34, 36] responses. This inconsistency in the findings may be attributed to the difference in animal models used in the studies [37] as well as the study design, such as vaccine schedule and stimulation condition. In general, the Th2 dominant response is the common CMI in aP vaccine-based studies. In this study, hBp was included as one of the stimulators to indirectly examine the effects of natural exposure, while vaccine antigens were used as stimulators to evaluate the response to the aP vaccine. After exposure to the stimulators, INF-γ, IL-17, and IL-5 showed significant differences between stimulators that were used but no differences between the positive control group and study groups. Notably, in the hBp + antigen stimulator group, the mean INF-γ level of the 3 vaccinated groups was 12,551.69 pg/mL, thereby revealing a difference of more than 5-fold when compared with the mean 2289.63 pg/mL in the antigen stimulator, suggesting that induction of INF-γ
may vary according to the type of simulator used for assay, and this can be applied to the other cytokines. Regardless of stimulators, the levels of INF-γ and IL-5 were significantly higher compared to the saline vaccinated negative control group, indicating that Th1 (INF-γ)/Th2 (IL-5) adaptive immunity was induced (Fig. 3B). This result is consistent with previous studies showing that the aP vaccine primarily induces the Th2 response but induces a dominant Th1 response when exposed to natural pertussis [38–41]. However, in this study, there are some limitations due to the in vitro system, and natural pertussis exposure could be substituted by hBp indirectly. In addition, the results of the intranasal challenge test using the clinical pertussis strain for real and reliable assessment showed that all vaccinated groups cleared the pathogen from Day 2 post-challenge, and by Day 5, the pathogen was hardly found in the lungs, thereby confirming the similar efficacy of the booster vaccines in the three vaccinated groups (Fig. 4).

Conclusions

GC Pharma’s enhanced GC311 Tdap vaccine addresses the limitations of the previous GC311 Tdap vaccine, wherein a lower anti-FHA antibody response is observed compared to that of the commercially available product. Our study outcomes confirmed that after booster vaccination, the humoral as well as the CMI responses were comparable to those of the commercially available product with equivalent efficacy against the clinical strain. Our findings present strong evidence that similar findings may be obtained in the phase II clinical trial that is currently being carried out.

Abbreviations

aP: acellular Bordetella pertussis; CFU: colony forming unit; CMI: Cell mediated immunity; DT: diphtheria toxoid; DTaP: diphtheria-tetanus-acellular pertussis; FHA: filamentous hemagglutinin; PRN: pertactin; PT: pertussis toxin; PWM: pokeweed mitogen; SEM: standard errors of the means; Tdap: tetanus-reduced dose diphtheria-acellular pertussis; TT: tetanus toxoid; WP: whole cell pertussis

Declarations

Acknowledgements

Not applicable.

Authors’ contributions

JHK and DHH designed the study. JAK, KRK and DHH conducted the experiments and analysed the data. KRK and JHK wrote the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Consent for publication**

Not applicable.

**Competing interests**

There is no conflicts of interest in this study.

**Ethics approval**

All animal research procedures were performed in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals and the Guidelines and Policies for Rodent Experiments provided by the IACUC (Institutional Animal Care and Use Committee) in the School of Medicine, The Catholic University of Korea. (Approval number: CUMS-2019-0100-01).

**Funding**

This study was supported by Green Cross Pharma (Yongin, Korea, Grant No.5-2018-D0083-0001, 5-2019-D0083-00002).

**References**

1. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California Pertussis Epidemic, 2010. The Journal of pediatrics. 2012;161(6):1091-6.

2. Chiappini E, Stival A, Galli L, de Martino M. Pertussis re-emergence in the post-vaccination era. BMC infectious diseases. 2013;13:151.

3. Cherry JD. Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. The New England journal of medicine. 2012;367(9):785-7.

4. Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, et al. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2014;19(33).

5. Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerging infectious diseases. 2014;20(4):626-33.

6. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18(9):E340-6.
7. Li L, Deng J, Ma X, Zhou K, Meng Q, Yuan L, et al. High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016. Emerging infectious diseases. 2019;25(12):2205-14.
8. Lee SY, Han SB, Kang JH, Kim JS. Pertussis Prevalence in Korean Adolescents and Adults with Persistent Cough. Journal of Korean medical science. 2015;30(7):988-90.
9. Lee SY, Han SB, Bae EY, Kim JH, Kang JH, Park YJ, et al. Pertussis seroprevalence in korean adolescents and adults using anti-pertussis toxin immunoglobulin G. Journal of Korean medical science. 2014;29(5):652-6.
10. Kwon HJ, Yum SK, Choi UY, Lee SY, Kim JH, Kang JH. Infant pertussis and household transmission in Korea. Journal of Korean medical science. 2012;27(12):1547-51.
11. Han SB, Kang KR, Huh DH, Lee HC, Lee SY, Kim J-H, et al. Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model. Clin Exp Vaccine Res. 2015;4(1):75-82.
12. Kwon HJ, Han SB, Kim BR, Kang KR, Huh DH, Choi GS, et al. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. BMC infectious diseases. 2017;17(1):247.
13. Park C, Huh DH, Han SB, Choi GS, Kang KR, Kim JA, et al. Development and implementation of standardized method for detecting immunogenicity of acellular pertussis vaccines in Korea. Clin Exp Vaccine Res. 2019;8(1):35-42.
14. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901-6.
15. Boursaux-Eude C, Thiberge S, Carletti G, Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine. 1999;17(20-21):2651-60.
16. Bruss JB, Siber GR. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clinical and diagnostic laboratory immunology. 1999;6(4):464-70.
17. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
18. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907-16.
19. Giammanco A, Taormina S, Chiarini A, Dardanoni G, Stefanelli P, Salmaso S, et al. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough. Vaccine. 2003;21(17-18):1924-31.
20. Taranger J, Trollfors B, Lagergard T, Sundh V, Bryla DA, Schneerson R, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. The Journal of infectious diseases. 2000;181(3):1010-3.
21. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and
recommendations. Vaccine. 2012;30(35):5179-90.
22. Mazzilli S, Tavoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect newborns from pertussis infection. Annali di igiene : medicina preventiva e di comunita. 2018;30(4):346-63.
23. Winter K, Nickell S, Powell M, Harriman K. Effectiveness of Prenatal Versus Postpartum Tetanus, Diphtheria, and Acellular Pertussis Vaccination in Preventing Infant Pertussis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;64(1):3-8.
24. Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. Journal of medical microbiology. 2018;67(10):1426-56.
25. Mills KH, Barnard A, Watkins J, Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infection and immunity. 1993;61(2):399-410.
26. Ausiello CM, Lande R, Urbani F, Di Carlo B, Stefanelli P, Salmaso S, et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. The Journal of infectious diseases. 2000;181(6):1989-95.
27. Barbic J, Leef MF, Burns DL, Shahin RD. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infection and immunity. 1997;65(12):4904-8.
28. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. The Journal of experimental medicine. 1997;186(11):1843-51.
29. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature immunology. 2007;8(4):369-77.
30. Fedele G, Bianco M, Ausiello CM. The virulence factors of Bordetella pertussis: talented modulators of host immune response. Archivum immunologiae et therapiae experimentalis. 2013;61(6):445-57.
31. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(2):787-92.
32. Brummelman J, Wilk MM, Han WG, van Els CA, Mills KH. Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis. 2015;73(8):ftv067.
33. Vermeulen F, Verscheure V, Damis E, Vermeylen D, Leloux G, Dirix V, et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol. 2010;17(2):258-62.
34. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 2013;9(4):e1003264.
35. Reynolds E, Walker B, Xing D, Southern J, Asokanathan C, Dagg B, et al. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study. Vaccine. 2006;24(16):3248-57.

36. Brummelman J, Helm K, Hamstra HJ, van der Ley P, Boog CJ, Han WG, et al. Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation. Vaccine. 2015;33(12):1483-91.

37. Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Current opinion in immunology. 2019;59:72-8.

38. Ausiello CM, Lande R, Urbani F, la Sala A, Stefanelli P, Salmaso S, et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infection and immunity. 1999;67(8):4064-71.

39. He Q, Tran Minh NN, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infection and immunity. 1998;66(8):3796-801.

40. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gotheffors L, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology. 1998;93(1):1-10.

41. Edwards KM, Berbers GA. Immune responses to pertussis vaccines and disease. The Journal of infectious diseases. 2014;209 Suppl 1:S10-5.